Senator Cassidy Questions Trump Administration’s Tylenol Advisory
In Washington, Senator Bill Cassidy, who is also a licensed physician and chairs the Senate Committee focused on health policy, has publicly disagreed with the Trump administration’s recent advice suggesting that pregnant women avoid using Tylenol.
Cassidy (R-La.) leads the Senate Health, Education, Labor and Pensions (HELP) Committee and has stated that the majority of evidence does not establish a strong connection between the use of painkillers and an increase in autism diagnoses. He has urged the Trump administration to present any data that supports this claim.
“I understand and appreciate President Trump’s commitment to addressing this issue, and I support the Department of Health and Human Services,” Cassidy shared on social media. He went on to emphasize the importance of new data from HHS to confirm the administration’s stance. “There’s a clear need for effective pain management options for women during pregnancy, and this claim should be substantiated,” he added.
The president and his health officials have made significant claims about acetaminophen, the generic name for Tylenol, suggesting it could significantly heighten autism risk.
Research accumulated over years indicates that after aspirin and ibuprofen, Tylenol is one of the few pain relievers deemed safe during pregnancy. However, there are known risks associated with taking high doses of these medications, often for the developing fetus.
According to recent data from the Centers for Disease Control and Prevention, around one in 31 individuals in the U.S. was affected by autism in 2022, equating to approximately 31 children diagnosed per 1,000. This marks a steep rise compared to the year 2000, when about 150 children were diagnosed with neurological developmental disorders.
Robert F. Kennedy Jr., the HHS secretary, is a strong proponent of the administration’s efforts to address rising autism rates, and it’s worth noting that Cassidy has had his differences with Kennedy in the past. Earlier this year, Cassidy notably voted against confirming Kennedy for the HHS position after making public comments about Kennedy’s controversial views on vaccines.
Last week, Cassidy chaired a hearing that looked into the dismissal of former CDC director Susan Monares, which seemed to be linked to disagreements over vaccine policies.
The White House released a factsheet claiming that using acetaminophen during pregnancy, especially in the later stages, could lead to long-term neurological impacts on children. One study cited by the administration, from the ICAHN School of Medicine at Mount Sinai, suggested that high-quality studies could reveal a connection between prenatal acetaminophen exposure and increased autism and ADHD risks, as noted by Dr. Didier Prada. “Even a marginal increase in risk from such a widely used medication can have considerable public health consequences,” he remarked before the White House’s announcement.
However, this study did not definitively establish a direct link between the use of acetaminophen and autism in children.
Healthcare professionals have voiced significant concerns regarding the claims made by the White House. A statement pointed out that the presentation by HHS did not represent the full spectrum of scientific evidence and oversimplified complex factors contributing to neurological issues in children.
Tylenol’s manufacturer, Kembo, also strongly contested the administration’s claims, asserting, “Acetaminophen is the safest pain relief option for pregnant women when necessary. Without it, women may have to make unsafe choices, risking complications for both themselves and their babies.”
